3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
3
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Fibroadenoma
1
Colorectal Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Breast Diseases
1
Interventions
pembrolizumab
16
Cyclophosphamide
9
Nivolumab
7
atezolizumab
6
fludarabine
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
cabozantinib
4
Trastuzumab
4
budigalimab
3
Ipilimumab
3
Interleukin-2
3
Cisplatin
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
spartalizumab
2
sargramostim
2
poly ICLC
2
palbociclib
2
lenvatinib
2
epacadostat
2
durvalumab
2
avelumab
2
X-Rays
2
Sunitinib
2
Paclitaxel
2
Irinotecan
2
Interleukin-12
2
Immunoglobulin G
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
gadoterate meglumine
×
Breast
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled